Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.
Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.
Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.
Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.
An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.
Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.
The risk for prostate cancer is 30–60% higher in men who father children through assisted reproduction than in those who conceive naturally, shows a nationwide study conducted in Sweden.
Men with a BRCA2 mutation are more likely to be diagnosed with prostate cancer following annual prostate-specific antigen screening than men without the mutation, interim results from the multinational IMPACT study show.
Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.
Elderly patients with prostate cancer and pre-existing cardiovascular disease have a significantly higher short-term mortality risk following abiraterone acetate or enzalutamide treatment than those without CVD, US study findings indicate.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.
In men with metastatic castration-resistant prostate cancer bone pain is the strongest predictor of skeletal-related events, while the number of bone metastases is the strongest predictor of mortality, suggests an analysis of the US SEARCH database.
Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.
68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.
Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.
Current decision aids probably have no influence on whether physicians and patients discuss prostate cancer screening or decide to undergo screening, according to a systematic review and meta-analysis.
Older prostate cancer patients who use androgen deprivation therapy may be at increased risk for developing Alzheimer’s disease or dementia, findings indicate.
Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.